On October 22, Daiichi Sankyo announced that UHD® has been officially approved in China. The single drug is suitable for treating adult solid tumors with unresectable or metastatic HER2 expression with IHC 3+ who have received previous treatment or are unsatisfactory with alternative treatment plans. This indication is a conditional approval based on the results of a single-arm clinical trial. Full approval of this indication will depend on the clinical benefits of the confirmatory trials carried out. Destrastuzumab is a DXD antibody-conjugated drug specifically designed to target HER2. It was developed by Daiichi Sankyo and developed and commercialized in collaboration with AstraZeneca and Daiichi Sankyo.
Zhitongcaijing · 2d ago
Share
Listen to the news
On October 22, Daiichi Sankyo announced that UHD® has been officially approved in China. The single drug is suitable for treating adult solid tumors with unresectable or metastatic HER2 expression with IHC 3+ who have received previous treatment or are unsatisfactory with alternative treatment plans. This indication is a conditional approval based on the results of a single-arm clinical trial. Full approval of this indication will depend on the clinical benefits of the confirmatory trials carried out. Destrastuzumab is a DXD antibody-conjugated drug specifically designed to target HER2. It was developed by Daiichi Sankyo and developed and commercialized in collaboration with AstraZeneca and Daiichi Sankyo.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending